Skip to content

13F-HR filed by ARCH Venture Management, LLC

ARCH Venture Management, LLC filed this 13F-HR for the quarter ended 2026-09-30, accepted by EDGAR 2026-11-16 21:41:32 UTC, with 17 holding rows worth $1,613,349,389.

Accession
0001012975-26-001080
Filed
2026-11-16
Accepted by EDGAR
Ingested
Source
EDGAR live feed

Original filing

13F report for Q3 2026

A holdings report, 17 entries on the cover page, a total value of $1,613,349,389 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,613,349,389 with VALUE read as dollars as filed, 13F file number 028-19358. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
KARDIGAN INC485925101CMN15,042,036$221,870,031dollars as filed
PARABILIS MEDICINES INC COM698955101Stock6,412,780$207,068,666dollars as filed
VIR BIOTECHNOLOGY INC92764N102COM12,694,163$141,920,742dollars as filed
SANA BIOTECHNOLOGY INC799566104COM45,860,681$133,683,885dollars as filed
SEAPORT THERAPEUTICS INC81221K108COMMON STOCK6,294,951$126,969,162dollars as filed
RAPPORT THERAPEUTICS INC COM75383L102Stock3,728,738$125,285,597dollars as filed
SCHOLAR ROCK HLDG CORP80706P103COM2,345,711$113,344,756dollars as filed
MAZE THERAPEUTICS INC COM578784100Stock4,120,053$111,983,041dollars as filed
BEAM THERAPEUTICS INC07373V105COM4,540,132$111,006,227dollars as filed
ERASCA INC COM29479A108Stock7,091,557$103,962,226dollars as filed
908 DEVICES INC COM65443P102Stock5,725,045$70,647,055dollars as filed
PRIME MEDICINE INC74168J101COM18,486,894$56,477,461dollars as filed
LYELL IMMUNOPHARMA INC COM NEW55083R203Stock3,247,162$31,789,716dollars as filed
GENERATE BIOMEDICINES INC370920100COMMON STOCK1,944,426$29,205,294dollars as filed
NEUMORA THERAPEUTICS INC.640979100COM33,847,838$20,180,081dollars as filed
BOUNDLESS BIO INC10170A100COM2,694,095$6,762,178dollars as filed
Gossamer Bio, Inc.38341P201Common Stock, $0.0001 par value per share100,698$1,193,271dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001012975-26-001080this filing2026-11-16